Literature DB >> 10835049

Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin.

B C Knollmann1, B E Knollmann-Ritschel, N J Weissman, L R Jones, M Morad.   

Abstract

Overexpression of cardiac calsequestrin (CSQ) impairs Ca2+ signalling in murine myocytes, leading to marked cardiac hypertrophy. Here we report on contractile, histological and electrophysiological changes accompanying the development of cardiac hypertrophy and failure in CSQ-overexpressing mice. CSQ mice developed contractile dysfunction after 60 days of age, with only 40% survival at 6 months. Four- to 6-month-old CSQ mice revealed biventricular dilatation, cardiomyocyte hypertrophy, patchy interstitial fibrosis and tissue calcifications. Cardiac hypertrophy of CSQ mice was accompanied by progressive P-R and Q-T interval prolongation, conduction blocks, 2-fold prolongation of the ventricular action potential and increased cellular membrane capacitance. Remodelling of ionic currents included marked reduction of both density and absolute magnitude of transient outward (Ito) and inward rectifying (IK1) K+ currents. The density, but not the absolute magnitude, of basal and isoproterenol (isoprenaline)-stimulated Ca2+ current (ICa) was decreased by 42% and the inactivation kinetics of ICa were significantly slowed. Na+ current density was suppressed by 50%, but its steady-state activation and inactivation were shifted to more positive potentials. The density of Na+-Ca2+ exchange current was increased by 35%. In CSQ but not in control myocytes dialysed with cAMP, isoproterenol continued to enhance ICa. This apparent lower responsiveness of ICa to cAMP could be reversed by the non-hydrolysable cAMP analogue 8-Br-cAMP or the phosphodiesterase inhibitor IBMX, suggesting high phosphodiesterase activity of CSQ myocytes. In young CSQ mice (< 60 days) with compensated cardiac hypertrophy, only Ito was significantly suppressed. All other currents remained relatively intact. An increase in cardiac Ca2+-storage capability by overexpression of CSQ results in a dilated cardiomyopathy with tissue fibrosis, calcifications, impaired beta-adrenergic signalling and progressive remodelling of ionic currents. The extent of the changes in ionic currents was age dependent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835049      PMCID: PMC2269956          DOI: 10.1111/j.1469-7793.2000.t01-1-00483.x

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  34 in total

1.  Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies.

Authors:  R L Winslow; J Rice; S Jafri; E Marbán; B O'Rourke
Journal:  Circ Res       Date:  1999-03-19       Impact factor: 17.367

2.  Role of Ca2+ channel in cardiac excitation-contraction coupling in the rat: evidence from Ca2+ transients and contraction.

Authors:  L Cleemann; M Morad
Journal:  J Physiol       Date:  1991-01       Impact factor: 5.182

3.  A uniform enzymatic method for dissociation of myocytes from hearts and stomachs of vertebrates.

Authors:  R Mitra; M Morad
Journal:  Am J Physiol       Date:  1985-11

4.  Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression.

Authors:  M C Cho; A Rapacciuolo; W J Koch; Y Kobayashi; L R Jones; H A Rockman
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

5.  Enhanced Na(+)-Ca2+ exchange activity in cardiomyopathic Syrian hamster.

Authors:  S N Hatem; J S Sham; M Morad
Journal:  Circ Res       Date:  1994-02       Impact factor: 17.367

6.  Complete amino acid sequence of canine cardiac calsequestrin deduced by cDNA cloning.

Authors:  B T Scott; H K Simmerman; J H Collins; B Nadal-Ginard; L R Jones
Journal:  J Biol Chem       Date:  1988-06-25       Impact factor: 5.157

7.  Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure.

Authors:  D J Beuckelmann; M Näbauer; E Erdmann
Journal:  Circ Res       Date:  1993-08       Impact factor: 17.367

8.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1992-07-23       Impact factor: 91.245

9.  Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages.

Authors:  E Cerbai; M Barbieri; Q Li; A Mugelli
Journal:  Cardiovasc Res       Date:  1994-08       Impact factor: 10.787

10.  Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure.

Authors:  R Studer; H Reinecke; J Bilger; T Eschenhagen; M Böhm; G Hasenfuss; H Just; J Holtz; H Drexler
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

View more
  42 in total

1.  Luminal Ca(2+) content regulates intracellular Ca(2+) release in subepicardial myocytes of intact beating mouse hearts: effect of exogenous buffers.

Authors:  Dmytro Kornyeyev; Mariano Reyes; Ariel L Escobar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-09       Impact factor: 4.733

2.  Chronotropic response of cultured neonatal rat ventricular myocytes to short-term fluid shear.

Authors:  Ilka Lorenzen-Schmidt; Geert W Schmid-Schönbein; Wayne R Giles; Andrew D McCulloch; Shu Chien; Jeffrey H Omens
Journal:  Cell Biochem Biophys       Date:  2006       Impact factor: 2.194

3.  Kcnq1 contributes to an adrenergic-sensitive steady-state K+ current in mouse heart.

Authors:  Bjorn C Knollmann; Syevda Sirenko; Qi Rong; Alexander N Katchman; Mathew Casimiro; Karl Pfeifer; Steven N Ebert
Journal:  Biochem Biophys Res Commun       Date:  2007-06-15       Impact factor: 3.575

4.  Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives.

Authors:  Jian-Bing Shen; Kiran S Toti; Saibal Chakraborty; T Santhosh Kumar; Chunxia Cronin; Bruce T Liang; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2020-01-27       Impact factor: 3.765

5.  Striking In vivo phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro.

Authors:  Hiroshi Watanabe; Tao Yang; Dina Myers Stroud; John S Lowe; Louise Harris; Thomas C Atack; Dao W Wang; Susan B Hipkens; Brenda Leake; Lynn Hall; Sabina Kupershmidt; Nagesh Chopra; Mark A Magnuson; Naohito Tanabe; Björn C Knollmann; Alfred L George; Dan M Roden
Journal:  Circulation       Date:  2011-08-08       Impact factor: 29.690

Review 6.  Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Karim Sallam; Yingxin Li; Philip T Sager; Steven R Houser; Joseph C Wu
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

7.  Transmural heterogeneity of repolarization and Ca2+ handling in a model of mouse ventricular tissue.

Authors:  Vladimir E Bondarenko; Randall L Rasmusson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-04       Impact factor: 4.733

8.  Calsequestrin 2 deletion shortens the refractoriness of Ca²⁺ release and reduces rate-dependent Ca²⁺-alternans in intact mouse hearts.

Authors:  Dmytro Kornyeyev; Azade D Petrosky; Bernardo Zepeda; Marcela Ferreiro; Bjorn Knollmann; Ariel L Escobar
Journal:  J Mol Cell Cardiol       Date:  2011-09-29       Impact factor: 5.000

9.  Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.

Authors:  Björn C Knollmann; Nagesh Chopra; Thinn Hlaing; Brandy Akin; Tao Yang; Kristen Ettensohn; Barbara E C Knollmann; Kenneth D Horton; Neil J Weissman; Izabela Holinstat; Wei Zhang; Dan M Roden; Larry R Jones; Clara Franzini-Armstrong; Karl Pfeifer
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

10.  Functional properties of K+ currents in adult mouse ventricular myocytes.

Authors:  Judith Brouillette; Robert B Clark; Wayne R Giles; Céline Fiset
Journal:  J Physiol       Date:  2004-07-22       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.